Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Upon binding to CD38-expressing MM cells, isatuximab is thought to induce tumor cell killing via fragme...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chen, Song, Zhili, Wang, Anlai, Srinivasan, Srimathi, Yang, Guang, Greco, Rita, Theilhaber, Joachim, Shehu, Elvis, Wu, Lan, Yang, Zhi-Yong, Passe-Coutrin, Wilfried, Fournier, Alain, Tai, Yu-Tzu, Anderson, Kenneth C., Wiederschain, Dmitri, Bahjat, Keith, Adrián, Francisco J., Chiron, Marielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457083/
https://www.ncbi.nlm.nih.gov/pubmed/32922390
http://dx.doi.org/10.3389/fimmu.2020.01771

Ejemplares similares

Ejemplares similares